

Tecan has been granted DLReady™ certification by Promega

Tecan, a global leader in laboratory automation and detection, has been granted DLReady™ certification status for its high-end multimode readers Infinite® M1000 and Infinite F500, by Promega Corporation, USA, a provider of innovative solutions and technical support to the life sciences industry.

MEDICAL TECHNOLOGY The multimode microplate readers have met Promega's acceptance criteria for being certified as DLReady™ in the corresponding validation programme managed by Promega. The certification demonstrates compatibility with the Dual-Luciferase Assay and underlines the excellent injector and flash luminescence performance of Tecan's Infinite M1000 and Infinite F500 multimode microplate readers.

Most sensitive platform

The Infinite M1000 is Tecan's new, high-end, premium Quad4 Monochromators™-based multimode instrument, providing outstanding flexibility, sensitivity and speed for demanding applications in drug discovery, life sciences and research. Its new luminescence technology and injector option makes it the

"Its new luminescence technology and injector option makes it the obvious successor to Safire2"

obvious successor to Tecan's high performance Safire2™ microplate reader.

The Infinite F500, Tecan's high-end, filter-based multimode instrument, is Tecan's most sensitive filter-based detection platform yet. It is based on the latest technological developments to provide a multifunctional and modular system that rapidly analyses all your luminescence and fluorescence-based assays at outstanding sensitivity levels. The optional integration of reagent injectors (two injectors with selectable volumes), make this a powerful and versatile drug discovery tool in assay development and screening.



Tecan's Infinite® M1000 and Infinite F500 multimode readers. Photo © Tecan.

ScanBalt Forum & Biomaterials Days 2009



Restoration of the Baltic Sea; Limitations and possibilities
Kalmar, Sweden • October 6-9, 2009

The 8th ScanBalt Forum 2009 will focus on environmental issues regarding the Baltic Sea. The objective is to gather scientist, managers and government officials to disseminate experiences made and to discuss the possibilities and limitations of active restoration approaches to restore the Baltic Sea.

The aim of ScanBalt Forum and ScanBalt Biomaterials Days is to strengthen the cooperation within the ScanBalt BioRegion and to encourage networking.



WWW.SCANBALT.ORG/FORUM2009

Propeller gives boost to heart

Initial use on humans of the Reitan catheter pump developed for minimally invasive treatment of patients with cardiac failure is a resounding success.

MEDICAL TECHNOLOGY 10% of all heart attack patients risk suffering cardiogenic shock, with one in every two of these dying from it.

Cardiologist Dr. Oyvind Reitan from Sweden had long been aware of this problem. While he was relaxing from hospital-related

stress on his small sailing boat, the boat's collapsible propeller engine gave him an idea that has long since been patented. In the mid 1990s, he

carried out research in powerful mechanical cardiac support in the form of a propeller.

When folded up, it is very small and therefore easy to insert. Once folded out, surrounded by a cage that opens up to protect the surrounding body tissue, it offers extremely high pumping power. Contact with Swedish entrepreneur Lars Sunnanväder, the 'father' of many small start-up companies in Hechingen, the 'Silicon Valley of medical technology', finally brought the Reitan pump to the STERN BioRegion for further development, and is now being prepared for a global market launch by CardioBridge GmbH.

Initial use at the start of this year resulted in an immediate sensational effect. At the University Hospital of Lund, Sweden, a 65-year-old man with acute cardiac and re-

nal insufficiency was saved from the threat of renal failure. The pump, which is only around three millimetres wide when folded up, was inserted into the femoral artery in the groin and pushed right up into the aorta. Once extended, the propeller displayed its high flow power.

It works by relieving pressure on the heart and provides a flow to the organs to counteract the danger of multiple organ failure. A sustained improvement in the patient's circulation and renal function was achieved within only twelve hours and thus in a much shorter period than planned. Since then, it has been possible to stabilise 15 patients in Sweden and the UK using the Reitan pump, despite the patients' sometimes critical state.



Using minimally invasive treatment, the Reitan pump is pushed right up into the aorta, where the propeller relieves pressure on the heart and provides a flow to the organs to counteract the danger of multiple organ failure.

PHASEONE TRIALS



PhaseOneTrials A/S

Your first choice in phase I and phase II clinical trials

PhaseOneTrials is an independent CRO specialising in conduct of phase I and phase II clinical trials performed under the strictest safety and quality standards. We operate our own restricted-access 36 bed trial unit at Hvidovre University Hospital and have immediate and unique access to patients and exceptional medical competencies in an environment that always puts clinical excellence and safety first.

We deliver:

Professional phase I and phase II trials with accurate and reliable results, on time and within budget.

PhaseOneTrials A/S

Hvidovre University Hospital, Section 447
Kettegaard Alle 30, 2560 Hvidovre, Denmark

Please visit www.phaseonetrials.com